ensive treatment is recommended in persons who have had an ischemic stroke or transient ischemic
attack (TIA) and are beyond the hyperacute period. Angiotensin-converting enzymes and angiotensin receptor blockers
are recommended as first-choice medications for patients with
diabetes. Glucose control to near-normoglycemic levels (target hemoglobin A1C â±•7%) is recommended among diabetics to reduce microvascular complications and, with
lesser